Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ERBB3 M91I |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ERBB3 M91I | bladder carcinoma | sensitive | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) treatment inhibited viability of a bladder carcinoma cell line harboring ERBB3 (HER3) M91I in culture (PMID: 33473169). | 33473169 | |
| ERBB3 M91I | bladder carcinoma | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, a bladder carcinoma cell line harboring ERBB3 (HER3) M91I was resistant to Tykerb (lapatinib) in culture (PMID: 33473169). | 33473169 |